{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:25:10Z","timestamp":1793881510599,"version":"4.7.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre","id":[{"id":"https:\/\/ror.org\/0187kwz08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Wellcome Trust Discovery Award","id":[{"id":"https:\/\/ror.org\/029chgv08","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Foundation Fighting Blindness Clinical Research Fellowship Award"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/14712598.2026.2733200","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:10:16Z","timestamp":1789373416000},"page":"1091-1100","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa"],"prefix":"10.1080","volume":"26","author":[{"given":"Maram E. A.","family":"Abdalla Elsayed","sequence":"first","affiliation":[{"name":"University of Oxford","place":["Oxford, UK"]},{"name":"Oxford University Hospitals NHS Foundation Trust","place":["Oxford, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[{"name":"University of Oxford","place":["Oxford, UK"]},{"name":"Oxford University Hospitals NHS Foundation Trust","place":["Oxford, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69740-7"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0971"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/340848"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0596-35"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/78182"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.8.1571"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208707119"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817639116"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.005"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1118847109"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"e_1_3_4_14_1","unstructured":"U.S. Food and Drug Administration. Luxturna. FDA; [Updated 2022 Jun 9; cited 2026 Jun 13]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2022.2083181"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507484"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3649"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1206"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep11137"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1523201113"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep39179"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1242\/bio.016816"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109458"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2022.2163405"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2026.05.029"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.004"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.11.021"},{"key":"e_1_3_4_28_1","unstructured":"ClinicalTrials.gov. A clinical trial evaluating the safety and efficacy of AGTC-501 in patients with X-linked retinitis pigmentosa caused by RPGR mutations (NCT04850118). National Library of Medicine; [cited 2026 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04850118"},{"key":"e_1_3_4_29_1","unstructured":"Beacon Therapeutics. Beacon Therapeutics announces positive interim 9+ month results from DAWN trial and 36-month phase 2 skyline trial data for laru-zova in patients with X-linked retinitis pigmentosa. Beacon therapeutics. 2025 Sep 4 [cited 2026 Jun 13]. Available from: https:\/\/www.beacontx.com\/"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.05.034"},{"key":"e_1_3_4_31_1","unstructured":"Foundation Fighting Blindness. ARVO 2025\u00a0highlight: J&J\u2019s XLRP gene therapy didn\u2019t meet primary endpoint in phase 3 clinical trial. Foundation Fighting Blindness. 2025 May 15 [cited 2026 Jun 13]. Available from: https:\/\/www.fightingblindness.org\/"},{"key":"e_1_3_4_32_1","unstructured":"Frontera Therapeutics. Frontera Therapeutics doses first patient in a trial of FT-002 gene therapy for treatment of X-linked retinitis pigmentosa. Frontera therapeutics. 2023 Feb 16 [cited 2026 Jun 13]. Available from: https:\/\/www.fronteratherapeutics.com\/"},{"key":"e_1_3_4_33_1","unstructured":"ClinicalTrials.gov. Gene therapy for RPGR gene mutation-associated X-linked retinitis pigmentosa (NCT06492850). National Library of Medicine; [cited 2026 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06492850"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0763-1"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.6254"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2022.2152212"},{"key":"e_1_3_4_37_1","unstructured":"MeiraGTx Holdings plc. MeiraGTx announces the acquisition of botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa. MeiraGTx. 2026 Apr 16 [cited 2026 Jun 13]. Available from: https:\/\/investors.meiragtx.com\/"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/343180a0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36612"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2925.2925"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.93"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125631"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101672"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17726"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2018.168"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101316"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13022"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.06.017"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz7423"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac421"},{"key":"e_1_3_4_52_1","unstructured":"European Medicines Agency. Lumevoq: withdrawal of the marketing authorisation application. EMA; 2023 Apr 20 [cited 2026 Jun 13]. Available from: https:\/\/www.ema.europa.eu\/"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.06.028"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.023"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.10.003"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.08.032"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.8.6.44"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2733200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2733200","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2733200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:29:06Z","timestamp":1793878146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2733200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/14712598.2026.2733200"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2733200","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}